---
title: "COSCIENS Biopharma (CSCI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CSCI.US.md"
symbol: "CSCI.US"
name: "COSCIENS Biopharma"
industry: "生物技術"
---

# COSCIENS Biopharma (CSCI.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |

## Company Profile

COSCIENS Biopharma Inc.是一家生命科學公司，專注于開發和商業化針對美國、德國、哥倫比亞、英國及國際市場的化妝品、營養保健品和藥品。該公司通過活性成分和制藥兩個部門運營。公司提供的活性成分包括燕麥β-葡聚糖，一種用于降低膽固醇的咀嚼劑；來自酵母的β-葡聚糖，一種作為免疫增強劑的營養保健品膠囊；以及燕麥酰胺，一種用于減少炎症的營養保健品咀嚼劑，適用于醫療和美容行業。它還提供 Macrilen/Ghryvelin（macimorelin），這是一種口服可用的類肽生長激素釋放激素受體（GHSR-1a）激動劑，通過與 GHSR-1a 結合刺激生長激素的分泌，用于診斷成人生長激素缺乏...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:15.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 353 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.89% |  |
| Net Profit YoY | -264.94% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 9.44M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -113.08% | E |
| Profit Margin | -199.56% | E |
| Gross Margin | 35.43% | C |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.89% | A |
| Net Profit YoY | -264.94% | E |
| Total Assets YoY | -44.93% | E |
| Net Assets YoY | -72.94% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -50.11% | D |
| OCF YoY | 24.89% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.24 | D |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 74.25% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - COSCIENS Biopharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-113.08%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-199.56%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "35.43%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "24.89%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-264.94%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-44.93%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-72.94%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-50.11%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "24.89%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.24",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "74.25%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.52 | 146/606 | - | - | - |
| PB | 1.38 | 134/606 | 1.38 | 1.38 | 0.90 |
| PS (TTM) | 1.04 | 28/606 | 1.26 | 1.04 | 1.04 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.72 |
| Highest Target | 60.00 |
| Lowest Target | 60.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CSCI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CSCI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CSCI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.